Filing Overview
Registrant: Qilian International Holding Group Limited, although the request metadata identifies BGM Group Ltd. The filing is a Form 20-F annual report, filed February 15, 2024, covering the fiscal year ended September 30, 2023. It is not a quarterly filing for calendar Q4 2023.
The Cayman Islands holding company has no material operating activities of its own. Operations are conducted primarily in China through Gansu Qilianshan Pharmaceutical Co., Ltd. and subsidiaries under contractual variable-interest-entity arrangements. The company reports under U.S. GAAP.
Business Context
The group manufactures and sells oxytetracycline and licorice products, traditional Chinese medicine derivatives, heparin products, natural sausage casings and fertilizers. Products are sold in more than 20 provinces in China. Substantially all revenue is generated by the consolidated VIE and its subsidiaries.
- Ordinary shares outstanding at September 30, 2023: 35.75 million.
- Directors and executive officers beneficially owned 77.45% of the ordinary shares.
- The shares transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective December 15, 2023, continuing to trade under QLI.
Key Financial Metrics
| US$ millions, except per-share data | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | 46.5 | 64.9 | (28%) |
| Gross profit | 1.8 | 6.2 | (72%) |
| Gross margin | 3.8% | 9.6% | (5.8 pts) |
| Operating income (loss) | (2.6) | 2.1 | Turned negative |
| Net income (loss) | (8.1) | 1.4 | Turned negative |
| Net loss attributable to shareholders | (7.8) | 1.1 | Turned negative |
| EBITDA, non-GAAP | (6.9) | 2.8 | Turned negative |
| Basic and diluted EPS | $(0.22) | $0.03 | Declined |
FY2023 other expenses were $5.3 million, including a $5.5 million investment loss primarily related to a fair-value decrease in trading securities. The company also recorded $219,000 of income tax expense despite a pretax loss, mainly due to deferred tax provisions and a valuation allowance.
Revenue and Segment Performance
| Segment | FY2023 revenue | Year-over-year change | FY2023 gross margin |
|---|---|---|---|
| Oxytetracycline, licorice and TCMD | $29.2 million | (28%) | 6.0% |
| Heparin and sausage casings | $15.3 million | (35%) | (6.2%) |
| Fertilizer | $2.0 million | 84% | 47.0% |
Cash Flow, Liquidity and Debt
- Cash and cash equivalents at September 30, 2023: $7.5 million, down from $14.3 million.
- Current assets: $34.5 million; current liabilities: $6.7 million; total liabilities: $6.9 million.
- Net cash provided by operating activities: $312,000, compared with $12.7 million in FY2022.
- Net cash used in investing activities: $4.7 million, including capital expenditures, construction spending, intangible-asset purchases and a $1.0 million short-term investment.
- Net cash used in financing activities: $2.9 million, including $1.8 million of dividends and net debt repayment.
- Bank loans: $480,000 at year-end. Bank notes payable were zero, compared with $1.5 million in FY2022.
- Capital expenditures were approximately $3.7 million. FY2024 planned capital expenditures were estimated at $2.6 million for a Chongqing heparin facility.
Management stated that existing resources and operating cash flow should meet normal working-capital needs and debt obligations for at least the next twelve months, but also stated that additional financing will be needed to support expansion. The company estimates at least $22.26 million of financing may be required over the next three years.
Material Changes Versus the Prior Period
- Revenue fell 28%, primarily because of weaker demand for oxytetracycline, heparin and sausage-casing products. Management attributed weakness partly to China-U.S. and China-Europe trade conditions, excess domestic supply and reduced export-related demand.
- The oxytetracycline facility was shut down for two months to reduce inventory; sales volume fell 24% and selling prices fell 8%.
- Heparin prices fell 28%, and the product became subject to PRC centralized procurement beginning in February 2023, intensifying competition. The segment generated a gross loss.
- Licorice pricing was reduced 6% to gain market share, while volume increased 155%.
- Gross margin contracted sharply because of lower selling prices, higher unit costs and under-absorption of fixed manufacturing costs.
- Operating cash flow declined by 98%, largely reflecting the net loss, unfavorable changes in receivables and bank acceptance notes, and lower working-capital benefits than in FY2022.
- The company recognized a $5.5 million investment loss and reduced the reported fair value of its trading-securities investment to $13.9 million from $19.5 million.
- On January 30, 2024, the company agreed to redeem the trading investment in six phases between April 30 and September 30, 2024. The filing does not provide the expected redemption proceeds.
Outlook, Risks and Unusual Items
- Management plans to expand marketing, production capacity and pharmaceutical and chemical facilities, but execution depends on obtaining additional equity or debt financing.
- The company paid a one-time special dividend of $0.05 per share, or approximately $1.8 million, in March 2023. It does not expect to pay regular dividends in the foreseeable future.
- The company has a $3.2 million remaining commitment under an $8.5 million construction agreement for the Chongqing facility.
- The VIE agreements provide contractual control and economic rights but have not been tested in a PRC court. The company does not own Gansu QLS directly; adverse regulatory action could result in loss of control and deconsolidation.
- PRC regulatory, foreign-investment, cybersecurity, data-privacy, foreign-exchange and overseas-listing requirements may change rapidly. The company states that no CSRC or CAC approval is currently required, but future offerings or regulatory changes could require filings or approvals.
- Gansu QLS has not fully contributed required social insurance for some employees, and Chengdu QLS has not established employee housing-fund accounts. Potential remediation, fines or compulsory enforcement could result.
- Internal control over financial reporting was not effective at September 30, 2023 because in-house accounting personnel lacked sufficient U.S. GAAP and SEC-reporting expertise. Management is recruiting personnel and providing training; remediation is not assured.
- Customer concentration remains material: two customers represented approximately 15% and 14% of FY2023 revenue. The company generally lacks long-term supply agreements with major customers.
- Cash held in PRC financial institutions is subject to local deposit-protection limits and RMB convertibility and remittance restrictions.
- The filing states that its auditors are PCAOB-registered and have been inspected, reducing—but not eliminating—HFCA-related delisting risk.
Most Important Facts to Verify
- Confirm that the intended issuer is Qilian International Holding Group Limited, ticker QLI, rather than BGM Group Ltd.
- Reconcile the filing’s annual reporting period ending September 30, 2023 with any requested “2023 Q4” analysis.
- Review the audited financial statements and valuation support for the $13.9 million trading-securities investment and its planned 2024 redemption.
- Assess whether the company can fund the $3.2 million construction commitment, planned capital expenditures and stated three-year financing requirement without material dilution.
- Monitor whether the VIE agreements remain enforceable and whether any PRC regulatory action could cause deconsolidation.
- Track remediation of the material weakness in internal control over financial reporting.
- Verify the status of social-insurance and housing-fund compliance, required permits and any related penalties or contingencies.
- Evaluate customer concentration, pricing pressure, centralized procurement effects and the sustainability of fertilizer profitability.